JudithSilversteinCurrierMD

Infectious Disease • Los Angeles, CA

HIV/AIDS Medicine

Professor of Medicine, UCLA-David Geffen School of Medicine

Join to view full profile

Dr. Currier is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Currier's full profile

Already have an account?

Office
11075 Santa Monica Blvd
Ste 100
Los Angeles, CA 90025

Summary

Dr. Judith Currier is Professor of Medicine and Chief of the Division of Infectious Diseases at the David Geffen School of Medicine at UCLA. She serves as Chair of the AIDS Clinical Trials Network, a global group of investigators focused on improving treatment for HIV and related co-infections. She received her medical degree from Geisel School of Medicine at Dartmouth and completed training in Infectious Diseases and Epidemiology and has been in practice 32 years. She specializes in HIV medicine and is the Co-Director of the UCLA Center for Clinical AIDS Research and Education.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Infectious Disease, 1988 - 1991
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
Geisel School of Medicine at DartmouthClass of 1985

Certifications & Licensure

CA State Medical License 1993 - 2026
GA State Medical License Active through 2013
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com

Clinical Trials

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss
Completed
Phase 1
Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
Completed
Phase 1
Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy Start of enrollment: 1997 Oct 01
Completed
Not Applicable
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
Completed
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
Completed
Phase 2
Carotid Artery Thickness in HIV Infected and Uninfected Adults
Completed
Effects of Maternal Anti-HIV Treatment on Infants Born to HIV-Infected Women Start of enrollment: 2006 Jun 01
Completed
Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women Start of enrollment: 2005 Oct 01
Completed
Not Applicable
Raltegravir Therapy for Women With HIV and Fat Accumulation Start of enrollment: 2008 Sep 01
Completed
Phase 2
Comparative Study of Three NNRTI-Sparing HAART Regimens Start of enrollment: 2009 May 01
Completed
Phase 3
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women Start of enrollment: 2010 Jan 01
Completed
Phase 4
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) Start of enrollment: 2014 Jan 01
Completed
Phase 2
Therapeutic Vaccination in Treated HIV Disease Start of enrollment: 2018 Aug 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2.
Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, Urvi M Parikh, Amy Heaps
JCI Insight. 2024-12-20
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial.
Márton Kolossváry, Samuel R Schnittman, Markella V Zanni, Kathleen V Fitch, Carl J Fichtenbaum
JAMA Cardiology. 2024-12-11
1 citations
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback.
Nathaniel Bloom, Sydney I Ramirez, Hallie Cohn, Urvi M Parikh, Amy Heaps
The Journal of Infectious Diseases. 2024-11-15

Journal Articles

Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Grou...
Steven G Deeks, James H Stein, Carl Fichtenbaum, Judith S Currier, Priscilla Y Hsue, Eric S Daar, Ahmed Tawakol, Michael Lederman, Tanvir Bell, Diane Havlir, Clinical Infectious Diseases
Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large HIV Treatment-Naive Clinical Trial
Raphael J Landovitz, Judith S Currier, Clinical Infectious Diseases
Lower Pretreatment Gut Integrity Is Independently Associated with Fat Gain on Antiretroviral Therapy
Judith S Currier, Peter W Hunt, Clinical Infectious Diseases

Other

Mycobacterium avium complex (MAC) infections in HIV-infected patients
Currier JS
http://www.uptodate.com/contents/mycobacterium-avium-complex-mac-infections-in-hiv-infected-patients
UpToDate, Wolters Kluwer Health - 2012-09-28
Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients
Currier JS, Leibowitz MR
http://www.uptodate.com/contents/overview-of-nontuberculous-mycobacteria-excluding-mac-in-hiv-infect
UpToDate, Wolters Kluwer Health - 2013-02-18
Epidemiology of cardiovascular disease and risk factors in HIV-infected patients
Currier JS
http://www.uptodate.com/contents/epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infe
UpToDate, Wolters Kluwer Health - 2013-02-07
Management of dyslipidemia and cardiovascular risk in the HIV-infected patient
Currier JS
http://www.uptodate.com/contents/management-of-dyslipidemia-and-cardiovascular-risk-in-the-hiv-infec
UpToDate, Wolters Kluwer Health - 2012-10-22
Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients
Currier JS
http://www.uptodate.com/contents/pathogenesis-and-biomarkers-of-cardiovascular-disease-in-hiv-infect
UpToDate, Wolters Kluwer Health - 2013-01-11
Join now to see all

Press Mentions

ACTG Announces Publication of Pivotal Hepatitis C Study in Clinical Infectious DiseasesMarch 21st, 2023
UC San Diego Participates in National Trial to Assess Potential Treatment for Human MonkeypoxOctober 27th, 2022
ACTG Presents Data Showing Success of Hepatitis B Vaccine Among People Living with HIV at IDWeek 2022October 20th, 2022
Join now to see all

Grant Support

Optimizing Antiretroviral Therapy In HIVNational Institute Of Allergy And Infectious Diseases2009–2012
Clinical Research Facilitation CoreNational Institute Of Allergy And Infectious Diseases2008–2012
UCLA AIDS Prevention And Treatment Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2007–2012
Prospective Evaluation Of Antiviral Therapy And Cardiac HealthNational Heart, Lung, And Blood Institute2008–2011
Phase II, Randomized, Double-Blind Study Of The Safety And Efficacy Of SCH 41National Center For Research Resources2006–2010
A Phase IV, Prospective, Randomized, Open-Label Evaluation Of The Efficacy OfNational Center For Research Resources2006–2010
A Phase Ii/Iii, Randomized, Double-Blind, Placebo-Controlled Trial Of UridineNational Center For Research Resources2007–2009
Sex Differences In Pharmacokinetics Of Lopinavir/Ritonavir Among HIV-1 InfectNational Center For Research Resources2007–2008
A Pilot Study Of The Safety, Efficacy, And Tolerability Of Ezetimibe (Zetia?)National Center For Research Resources2007–2008
Stavudine Drug Levels And The Risk Of Metabolic Toxicity In Patients ReceivinNational Center For Research Resources2006–2008
Fat Redistribution And Metabolic Change In HIV Infection: Protocol 2 (Fram 2)National Center For Research Resources2006–2007
Metabolic Complication Of HIV InfectionNational Institute Of Allergy And Infectious Diseases2003–2007
Adults AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (AllrNational Center For Research Resources2005–2006
A Prospective Observational Study Of Virologic And Immunologic Changes In HIVNational Center For Research Resources2005–2006
AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2004–2006
STD Faculty Expansion ProgramNational Center For Hiv, Viral Hepatitis, Stds And Tb Prevention2003–2006
Stavudine Drugs &Risk Metabolic Toxicity: PATS Recv Antiretroviral Therapy:AidsNational Center For Research Resources2005
A Study Investigating Plasma Levels Of D-Chiro-Inositol In Patients With HIVNational Center For Research Resources2005
A Randomized, Double-Blind, Placebo-Controlled Study Of Metformin And RosigliNational Center For Research Resources2005
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Of Once-WeeklyNational Center For Research Resources2005
Study Investigating Plasma Levels Of D-Chiro-InositolNational Center For Research Resources2004
Stavudine Drug Levels And The Risk Of Metabolic Toxicity In Patients Receivin...National Center For Research Resources2004
Randomized, Double-Blind, Placebo-Controlled Study OfNational Center For Research Resources2004
Pilot Study Of The Safety, Efficacy, And TolerabilityNational Center For Research Resources2004
Phase II, Randomized, Double-Blind, Placebo-ControlledNational Center For Research Resources2004
Adults AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (Allr...National Center For Research Resources2004
Viracept (BID) And Sanquinavir (BID) Compared With Tid Dosing In HIVNational Center For Research Resources1999–2002
Actg365--Steady State PK Interaction Study Of Indinavir &RifabutinNational Center For Research Resources1999–2002
24 Week Study Of Indinavir Sulfate 800 MG Q8h Versus 1200 MG Q12hNational Center For Research Resources1999–2002
Phase I/II Trial Of Nandrolone Decanoate In Women W/ HIV Associated Weight LossNational Center For Research Resources1998–2002
Phase II, Randomized Trial Of Amprenavir As PART Of Dual Protease InhibitorNational Center For Research Resources1999–2001
Phase II, Randomized Study Of The Safety And Efficacy Of ViraceptNational Center For Research Resources1998–1999